Cingulate (CING) Net Equity Issued and Repurchased (2023 - 2026)
Cingulate's (CING) quarterly Net Equity Issued and Repurchased came in at $4.5 million in Q4 2025, up 201.94% YoY from $1.5 million in Q4 2024, and up 291.87% on a QoQ basis from $1.1 million in Q3 2025.
Cingulate (CING) Net Equity Issued and Repurchased (2023 - 2026) Analysis & Trends
Cingulate (CING) has 3 years of Net Equity Issued and Repurchased data on file, last reported at $4.5 million in Q4 2025.
- Quarterly Net Equity Issued and Repurchased rose 201.94% year-over-year to $4.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.1 million (down 49.18% YoY) and the FY2025 annual result came in at $10.2 million, down 60.76% from the prior year.
- Net Equity Issued and Repurchased improved to $4.5 million in Q4 2025, from $1.1 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $9.9 million in Q1 2024 to a low of $100978.0 in Q2 2023.
- A 3-year average of $3.0 million and a median of $1.7 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased soared 250.83% — and 2025, when it slumped 81.13%.
- Tracing CING's Net Equity Issued and Repurchased over 3 years: stood at $819538.0 in 2023, then jumped by 81.76% to $1.5 million in 2024, then surged by 201.94% to $4.5 million in 2025.
- The last three Net Equity Issued and Repurchased figures came in at $4.5 million (Q4 2025), $1.1 million (Q3 2025), and $1.9 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | 5.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.06 Mn |
| Jun 30, 2026 | 5.06 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 1.49 Mn |
| Dec 31, 2024 | 1.49 Mn |
| Sep 30, 2024 | 6.08 Mn |
| Sep 30, 2024 | 6.08 Mn |
| Jun 30, 2024 | 354,259.00 |
| Jun 30, 2024 | 354,259.00 |
| Mar 31, 2024 | 9.89 Mn |
| Mar 31, 2024 | 9.89 Mn |
| Dec 31, 2023 | 819,538.00 |
| Dec 31, 2023 | 819,538.00 |
| Sep 30, 2023 | 3.30 Mn |
| Sep 30, 2023 | 3.30 Mn |